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During normal aging or neurodegenerative diseases, neuronal survival and function
depend on protein homeostasis, which is regulated by multiple mechanisms, including the
microRNA (miRNA) pathway. In different cells types, the absence of Dicer, a key miRNA
processing enzyme, leads to neurodegeneration through cell-autonomous and non-cell-
autonomousmechanisms. Loss of certainmiRNAs also causes neurodegeneration in some
model organisms. On the other hand, miRNA expression is misregulated in patients with
different neurodegenerative diseases. Thus, the miRNA pathway appears to be essential
in the pathogenesis of several age-dependent neurodegenerative conditions; however, our
understanding of the underlying mechanism remains rudimentary.The precise causal rela-
tionships between speciﬁc miRNAs and neurodegeneration in humans need to be further
investigated.
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INTRODUCTION
Alzheimer’s disease (AD), frontotemporal dementia (FTD),
Parkinson’s disease (PD), and other neurodegenerative disorders
are a major health problem in both developed and developing
countries (Hampel et al., 2011; Reitz et al., 2011; Wittchen et al.,
2011). Since no effective treatments are available, it is unlikely that
the adverse societal effects of these disorders will be substantially
alleviated in the near future. These disorders are characterized
by progressive neuronal dysfunction that initially affects selected
groups of neurons in specialized neuronal circuits. A number
of cellular and molecular mechanisms lead to neuronal demise.
Among them, neurotoxicity induced by misfolding, mislocaliza-
tion, or abnormally elevated concentrations of particular protein
species seems to be a common theme (Jucker and Walker, 2011;
Lee et al., 2012; Selkoe et al., 2012). Mutations in several genes that
are apparently functionally unrelated can cause the same neu-
rodegenerative disease. Multiple environmental factors (e.g., viral
infections and exposure to certain toxins) might also contribute
to the development of a neurodegenerative disease (Ahmed and
Wicklund, 2011; Gao and Hong, 2011). Much remained to be
learned about how the complex interactions of environmental
and genetic factors initially lead to the misregulation of protein
homeostasis and subsequently to neuronal dysfunction.
MicroRNAs (miRNAs) are small non-coding RNAs that post-
transcriptionally regulate gene expressionbydegrading their target
mRNAs or repressing their translation (Ambros et al., 2003; Bar-
tel, 2004; Ghildiyal and Zamore, 2009). Initially discovered in
Caenorhabditis elegans (Lee et al., 1993),miRNAs have been found
inplants, invertebrates,mammals, andhumans (Bartel, 2009). Two
major features of miRNAs indicate their potential contributions
to neurodegenerative diseases. First, miRNAs can simultaneously
regulatemany target transcripts, and up to 50% of all coding genes
may be regulated by miRNAs (Krol et al., 2010). Thus, miRNAs
are central regulators of genetic networks. Second,miRNAs ensure
stable protein levels under variable conditions and are there-
fore essential for the robustness of biological processes (Herranz
and Cohen, 2010). Given the importance of protein homeosta-
sis and the diversity of cellular pathways potentially leading to
neurodegeneration, it has been hypothesized that miRNAs might
contribute to neurodegenerative diseases (Eacker et al., 2009; Lau
and de Strooper, 2010; Sonntag, 2010).
In this review, we brieﬂy describe the biogenesis of miRNAs
and their potential involvement in the evolution of the human
brain. Then we will discuss accumulating evidence that miRNAs
are important contributors to neurodegenerative diseases. Indeed,
some observations suggest that miRNA alterations can disrupt
protein homeostasis and may be at the root of neurodegenerative
processes (Figure 2). Conversely, other data strongly suggest that
alteredmiRNA networks are a consequence of abnormal neuronal
physiology (Figure 3). Examples in speciﬁc neurodegenerative
diseases will be presented.
miRNA BIOGENESIS
Although several alternative mechanisms also exist (Yang and Lai,
2011), the canonical pathway for miRNA biogenesis involves a
primary transcript generated by RNA polymerase II (Lee et al.,
2004). The primary miRNA is cleaved by a nuclear complex con-
taining Drosha and DGCR8, giving rise to a hairpin precursor
molecule (pre-miRNA) of 70–100 nt (Lee et al., 2003; Han et al.,
2004). This pre-miRNA is exported to the cytoplasm,where Dicer,
a RNA-III nuclease, catalyzes the ﬁnal cleavage in the matura-
tion process, resulting in an imperfect RNA duplex (Hutvagner
et al., 2001). One strand (guide strand) is loaded into an RNA-
induced silencing complex (RISC) to bind the target mRNA; the
other strand (passenger strand) is usually destroyed (Chendri-
mada et al., 2005; Bartel, 2009).miRNAs control gene expression at
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the post-transcriptional level through imperfect base pairing with
speciﬁc sequences, located mostly in the 3′UTRs of mRNAs. After
recognition, miRNA–target interactions often result in mRNA
degradation or inhibition of mRNA translation (Krol et al., 2010;
Figure 1).
ROLE OF miRNA IN BRAIN EVOLUTION
Neurodegenerative diseases are considered devastating disorders
because they often impair cognitive and executive functions.
Understanding how the human brain acquired such functions is
a challenging task that might also provide important insights into
the mechanisms of neurodegeneration. It was noted four decades
ago that genetic differences among species do not account for
brain divergence and that brain evolution could have been dri-
ven by changes in gene expression levels (King andWilson, 1975).
Early comparative transcriptome analyses conﬁrmed this hypoth-
esis and revealed more human-speciﬁc than chimpanzee-speciﬁc
expression changes in the prefrontal cortex (PFC); no such changes
were observed in blood, liver, or other tissues (Enard et al., 2002;
Caceres et al., 2003). These ﬁndings supported the idea that brain-
speciﬁc changes in gene expression levels shaped the evolution of
the nervous system.
To determine whether miRNAs participated in this process,
miRNA expression proﬁles in human and chimpanzee brains were
compared (Berezikov et al., 2006). Many of the newly identiﬁed
brain miRNAs were expressed only in humans, and many were
restricted to primates. Another study reported that 10–35% of
miRNAs were expressed in the human brain but not in chim-














FIGURE 1 |The canonical miRNA biogenesis pathway. miRNAs are
produced from long Pol II transcripts (pri-miRNA). A nuclear complex
containing Drosha (purple oval) and DGCR8 (pink oval) cleaves the primary
transcript and generates a precursor miRNA (pre-miRNA). After nuclear
export, pre-miRNA is further processed by Dicer (blue croissant). Then,
Ago2 (yellow oval) binds to the complex formed by miRNA duplex and Dicer.
Ago2 induces Dicer dissociation and the release of the passenger strand
from the complex. Finally, other proteins, such as GW182 (dark blue),
associate with Ago2 and form a RISC complex that recognizes and then
silences (by mRNA degradation and/or translation inhibition) a target mRNA.
developmental proﬁles of brain miRNAs and their target genes
showed the fastest rates of human-speciﬁc evolutionary change
(Somel et al., 2011). Although experimental evidence is still lack-
ing, it is an attractive hypothesis that rapidly evolving miRNAs
in the human brain are essential for neuronal function and
maintenance.
GLOBAL LOSS OF miRNAs CAUSES NEURODEGENERATION
Genetic disruption of miRNAs biogenesis pathways has been used
to probe the potential link between miRNAs and neurodegenera-
tion. In mouse cerebellar Purkinje cells, conditional knockout of
Dicer leads to age-dependent cerebellar degeneration and ataxia
(Schaefer et al., 2007). Cell-type speciﬁc deletion of Dicer in stri-
atal, retinal, spinal, and cortical neurons produced similar results
(Cuellar et al., 2008; Damiani et al., 2008; Davis et al., 2008; Hara-
mati et al., 2010). Dicer deletion also altered the phosphorylation
pattern of tau before neuronal cell loss (Hebert et al., 2010), indi-
cating that some mechanisms of neurodegeneration might be
controlled through miRNAs. Of note, neurodegeneration in the
absence of Dicer could also result from the toxic accumulation of
pre-miRNAs or from the loss of other Dicer functions unrelated
to miRNAs biogenesis. However, reduced production of a small
proportion of miRNAs as a result of DGCR8 haploinsufﬁciency
also leads to neuronal dysfunction (Stark et al., 2008; Fenelon
et al., 2011; Schoﬁeld et al., 2011), supporting the notion that
neurodegeneration could indeed arise from loss of miRNAs.
Glial cell defects may also profoundly inﬂuence neuronal sur-
vival (Ilieva et al., 2009; Prinz et al., 2011). Indeed, neurodegen-
eration ensues after targeted deletion of Dicer in astrocytes (Tao
et al., 2011), oligodendrocytes (Shin et al., 2009), and Schwann
cells (Pereira et al., 2010; Verrier et al., 2010; Wu et al., 2012).
Thus, alteration of miRNA networks has the potential to disrupt
neuronal function in a cell-autonomous or non-cell-autonomous
manner and lead to neurodegenerative phenotypes.
LOSS OF INDIVIDUAL miRNAs LEADS TO
NEURODEGENERATION
Genetic analyses have revealed essential roles for speciﬁc miRNAs
in long-term neuronal survival, for example in mice lacking miR-
124-1 (Sanuki et al., 2011), one of the most well studied miRNAs
in neuronal development (Gao, 2010). The mouse genome has
three miR-124 loci (miR-124-1, -2, and -3). Deletion of miR-124-
1, the dominant source of this miRNA, increases apoptosis in the
hippocampus and retina, causing a signiﬁcant decrease in brain
size. Furthermore, in the tail-suspension test, adult mutant mice
exhibit a front and hind limb clasping response, a commonpheno-
type in mouse models of neurodegenerative disorders. This effect
seems to be mediated by regulation of the transcription factor
Lhx2 (Sanuki et al., 2011). It is unclear whether the neurodegen-
eration also reﬂects the absence of miR-124’s well-documented
developmental functions (Cao et al., 2007;Visvanathan et al., 2007;
De Pietri Tonelli et al., 2008; Cheng et al., 2009; Maiorano and
Mallamaci, 2009). This question could be answered by using a
conditional knockout approach.
Another miRNA that might be involved in neuronal survival
is miR-8 (Karres et al., 2007), which is not brain-speciﬁc and
has a complex pattern of expression. Mutant ﬂies lacking miR-8
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have limb and wing defects and increased apoptosis in the central
nervous system.Moreover, concomitant decrease of the transcrip-
tional repressor atrophin in miR-8 mutant ﬂies partially rescued
the phenotypes (Karres et al., 2007). It remains to be determined
whether miR-8 contributes to neurodegeneration in mammals.
miRNAs IN NEURODEGENERATIVE DISEASES
Microarray studies have shown that the brain expresses a wide
range of miRNAs, suggesting that these small RNAmolecules par-
ticipate in nervous systemphysiology (Lagos-Quintana et al., 2002;
Miska et al., 2004; Lim et al., 2005; Manakov et al., 2009). More
importantly, proﬁling studies revealed profound changes in sev-
eral miRNAs (i.e.,miR-9,miR-29 cluster,miR-107,miR-125b, and
miR-128) in patient brains such as that of AD patients (Kim et al.,
2007; Lukiw, 2007; Hebert et al., 2008; Johnson et al., 2008; Wang
et al., 2008, 2011; Nunez-Iglesias et al., 2010). Although these
global changes in miRNA expression under pathological condi-
tions should be interpreted cautiously, they support the notion
that dysregulation of miRNAs networks is a common theme in
neurodegenerative diseases.
ALZHEIMER’S DISEASE
A pathological hallmark of AD, the most prevalent neurodegen-
erative disease, is the accumulation of plaques formed by short
β-amyloid (Aβ) peptides, commencing in the hippocampus, and
spreading progressively throughout the brain (Ballard et al., 2011;
Selkoe et al., 2012). It is likely the accumulation is caused by both
increased production and impaired clearance of Aβ. Aβ peptides
exert toxic effects and elicit an inﬂammatory response. Both may
contribute to disrupt neuronal homeostasis and alter the integrity
of neuronal networks involved in learning, memory, and other
cognitive functions. Aβ peptides are generated through proteolytic
cleavage of the amyloidprecursor protein (APP)byγ-secretase and
β-site APP-cleaving enzyme 1 (BACE1; O’Brien andWong, 2011).
Amyloid precursor protein and BACE1 each contain several
miRNA target sites in their 3′UTRs. Several miRNAs have been
reported to repress APP expression, including miR-16, miR-101,
miR-106a, and miR-520c (Patel et al., 2008; Liu et al., 2010; Long
and Lahiri, 2011). miR-137 and miR-181c regulate serine palmi-
toyltransferase, which modulates the Aβ level (Geekiyanage and
Chan, 2011). Interestingly, polymorphisms in miRNA binding
sites in the 3′UTR of APP gene could inﬂuence the binding efﬁ-
ciency of these miRNAs. Thus, miRNAs might ﬁne tune APP
expression, which may enhance or limit the risk of AD (Delay
et al., 2011).
A signiﬁcant decrease in neuronal miR-107 expression and a
parallel increase in BACE1 have been observed in AD patients
(even those at the earliest stages of AD;Wang et al., 2008,2011;Nel-
son andWang, 2010). The 3′UTR of BACE1mRNA has functional
binding sites for miR-29 (Hebert et al., 2008), miR-107 (Wang
et al., 2008), and miR-124 (Fang et al., 2012). Interestingly, miR-
107 also controls the expression of other proteins relevant to AD
pathology, such as coﬁlin (Yao et al., 2010), an actin-binding pro-
tein that accumulates in cytoplasmic inclusions known as Hirano
bodies (Hirano, 1994). Thus, a single miRNA deregulation could
activate multiple potentially pathogenic cascades upstream of Aβ
accumulation.
Another possibility is that alterations in miRNAs in AD brain
are a consequence of amyloid deposits. For instance, miR-106b is
aberrantly expressed in APPswe/PSE9 mice (Wang et al., 2010a),
and miR-146a levels are increased in AD brains and in sev-
eral mouse models of AD (Li et al., 2011). In vitro exposure
of hippocampal neurons to Aβ peptides preferentially decreases
the levels of mature miRNAs (only a small fraction of miRNAs
were upregulated; Schonrock et al., 2010). miRNAs were simi-
larly deregulated in the hippocampus of APP23 mice at the onset
of plaque formation. Overall, these studies suggest that miRNA
deregulation is an essential pathogenic mechanism that is induced
by Aβ aggregation and contributes to the progression and severity
of AD.
POLYGLUTAMINE DISEASES
Polyglutamine (polyQ) diseases are a group of nine neurodegener-
ative disorders caused by an unstable CAG expansion in the coding
region of their respective associated genes (Orr and Zoghbi, 2007).
Apart from this common feature, polyQ diseases have distinct
clinical presentations, and the proteins involved in these diseases
have no structural/functional homology (Table 1). Huntington
disease (HD), the most frequent polyQ disease, is characterized
by the progressive loss of striatal neurons and motor impair-
ment (typically resulting in the involuntary writhing movements
called chorea) and is often associatedwith cognitive andbehavioral
deﬁcits (Shoulson and Young, 2011).
The causal mutation in HD is an expanded repetition of the
CAGtrinucleotide in theﬁrst exonof the gene encodinghuntingtin
(HTT; Gilliam et al., 1987), a large protein (3300 amino acids)
whose functions remains mostly unknown. HTT associates with
Ago2 in P-bodies, and HTT depletion impairs miRNA-mediated
gene silencing (Savas et al., 2008). Expanded HTT may sequester
RNA processing factors in the cytoplasm (Jiang et al., 2011).
miRNAs were implicated in HD pathogenesis by two lines of
evidence. First, the levels of repressor element 1 silencing tran-
scription (REST) factor, amajor pathogenic pathway inHD(Buck-
ley et al., 2010), is elevated in HD neurons, resulting in repression
of hundreds of key neuronal genes (Zuccato et al., 2003, 2007;
Johnson et al., 2010b). Canonical and non-canonical REST bind-
ingmotifs have beenmapped in close proximity to 22miRNA sites
in the human genome, including several miRNAs that are abun-
dant in neurons (Bruce et al., 2004; Jothi et al., 2008; Yu et al.,
2011). Could abnormal REST deregulate miRNAs network in HD
patients? REST and its cofactor coREST possess functional tar-
get sites for miR-9 and miR-9∗, respectively (Packer et al., 2008),
and miR-9 and miR-9∗ (together with miR-7, miR-124, miR-132,
and other miRNAs) are downregulated in HD patients (John-
son et al., 2008; Packer et al., 2008; Marti et al., 2010). miRNA
deregulation in HD was conﬁrmed by proﬁling studies in animal
models, although there was a high degree of variability among
the models (Lee et al., 2011). These observations strongly sug-
gest that altered miRNA transcription is a major event in HD
pathogenesis.
Besides HD, there are eight other polyQ diseases:
dentatorubral–pallidoluysian atrophy, spinal and bulbar muscu-
lar atrophy, and spinocerebellar ataxia (SCA) 1, 2, 3, 6, 7, and 17
(Gatchel and Zoghbi, 2005). In ﬂy models of SCA3, reduction of
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Table 1 | List of miRNAs and the neurodegenerative diseases to which they have been associated.
miRNA Disease Type of evidence Mechanism Reference
miR-7 PD In vitro reporter assay Regulation of α-synuclein Doxakis (2010), Junn et al. (2009)
Overexpression in vitro
miR-8 miR-8 ﬂies Upregulation of atrophin Karres et al. (2007)
miR-9/9* HD Proﬁling studies REST–coREST Marti et al. (2010), Packer et al. (2008)
In vitro reporter assays
miR-9/9* ALS Proﬁling in mouse mode Neuroﬁlament expression Haramati et al. (2010)
miR-16 AD Proﬁling in mouse model Regulation of APP levels Liu et al. (2010)
Overexpression in vitro/in vivo
miR-19 SCA1 In vitro reporter assays Regulation of ataxin-1 Lee et al. (2008)
In vitro gain of function
miR-29 AD Proﬁling in patients Regulation of BACE1 levels Hebert et al. (2008)
In vitro reporter assay
Overexpression/blocking in vitro
miR-29b FTD In vitro reporter assay Regulation of progranulin Jiao et al. (2010)
Overexpression in vitro
miR-34 SCA3 overexpression in ﬂy Protective role Liu et al. (2012)
miR-101 AD In vitro reporter assays Regulation of APP levels Long and Lahiri (2011)
Overexpression/blocking in vitro
miR-101 SCA1 In vitro reporter assays Regulation of ataxin-1 Lee et al. (2008)
In vitro gain of function
miR-106a AD In vitro reporter assays Regulation of APP levels Patel et al. (2008)
Overexpression in vitro
miR-106b AD Expression in mouse model TGF-β Wang et al. (2010a)
miR-107 AD Proﬁling in patients Regulation of BACE1 levels Wang et al. (2008)
In vitro reporter assay
In situ hybridization in patients
miR-107 AD In vitro reporter assay Regulation of coﬁlin Yao et al. (2010)
Levels in mouse models
miR-107 FTD In vitro overexpression Regulation of progranulin Wang et al. (2010b)
miR-124 miR-124-1 knockout mouse Altered expression of Lhx2 Sanuki et al. (2011)
miR-124 AD Overexpression in vitro/in vivo Regulation of BACE1 levels Fang et al. (2012)
miR-130 SCA1 In vitro reporter assays Regulation of ataxin-1 Lee et al. (2008)
In vitro gain of function
miR-133b PD Proﬁling in patients ??? Kim et al. (2007)
miR-137 AD Proﬁling in patients Regulation of Aβ levels Geekiyanage and Chan (2011)
In vitro reporter assay
Blocking in vitro
miR-144 SCA1 Proﬁling in patients Regulation of ataxin-1 Persengiev et al. (2011)
In vitro reporter assay
miR-146a AD Proﬁling in patients Downstream of Aβ Li et al. (2011)
Expression in cell lines and mouse models
miR-153 PD In vitro reporter assay Regulation of α-synuclein Doxakis (2010)
Overexpression in vitro
miR-181c AD Proﬁling in patients Regulation of Aβ levels Geekiyanage and Chan (2011)
In vitro reporter assay
Blocking in vitro
miR-520c AD In vitro reporter assays Regulation of APP levels Patel et al. (2008)
Overexpression in vitro
miR-659 FTD–ALS Human polymorphism Regulation of progranulin Rademakers et al. (2008)
miRNA processing after knockout of Dicer1 markedly enhances
the toxicity induced by mutant ataxin-3 (Bilen et al., 2006). In
parallel genetic screens, a single miRNA, bantam, was identiﬁed as
a potent downstreammodulator of both polyQ and tau toxicity in
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ﬂies (Bilen et al., 2006). In a recent paper,miR-34 was shown to be
protective against expanded SCA3 (Liu et al., 2012). Subsequent
work suggested that miR-19, miR-101, and miR-130 are impor-
tant for the post-translational regulation of ataxin-1 (Lee et al.,
2008). Inhibition of those miRNAs enhanced the cytotoxicity of
polyQ-expanded ataxin-1 in human cells. Moreover, miR-144, a
highly conserved miRNA, also regulated ataxin-1 expression and
appeared to be associated with aging. Ataxin-1 levels are higher in
the cerebellum and cortex of SCA1 patients than in healthy aged
brains (Persengiev et al., 2011). On the other hand, ataxin-2might
be required for miRNA function (McCann et al., 2011), further
supporting the intimate association between miRNAs and polyQ
diseases.
PARKINSON’S DISEASE
Parkinson’s disease is a neurodegenerative disorder that primar-
ily affects movement. Clinical symptoms include bradykinesia
(decreased ability to start and continue movements), resting
tremor, and rigidity. These symptoms are due to the relatively
selective loss of dopaminergic neurons in the substantia nigra
(Dauer and Przedborski, 2003) and reﬂect the impairment of neu-
ronal networks important for regulating motor function. The past
two decades have witnessed signiﬁcant advances in the identiﬁ-
cation of distinct genetic loci at which pathogenic mutations are
associated with parkinsonism (for review, see Lesage and Brice,
2009; Zimprich, 2011). Most research is focused on genes that
have been conclusively linked to PD pathogenesis, including those
encodingα-synuclein, leucine-rich repeat kinase 2,PTEN-induced
putative kinase 1, parkin, and DJ-1.
Proﬁling studies of PD brains have revealed abnormalities in
miRNA content (Kim et al., 2007; Minones-Moyano et al., 2011).
One of the miRNAs found to be downregulated in these stud-
ies, miR-133b, plays a major role in the development of midbrain
dopaminergic neurons by regulating the transcription factor Pitx3
(Kim et al., 2007). miR-7 and miR-153 control the expression of
α-synuclein (Junn et al., 2009; Doxakis, 2010). Since intracellular
levels of this protein appear to be critical in mediating its toxicity,
deregulation of those miRNAs might lead to increased toxic levels
of α-synuclein.
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL
DEMENTIA
Amyotrophic lateral sclerosis (ALS) is a progressive, lethal, degen-
erative disorder characterized by the selective death of motor
neurons in the brain and spinal cord (Pasinelli and Brown, 2006;
Ferraiuolo et al., 2011).ALS sharesmany clinical, pathological, and
molecular features with FTD, the second most common early-
onset dementia (Ferrari et al., 2011). Clinically, FTD progresses
from an insidious onset of behavioral changes, impaired frontal
executive functions, and language deﬁcits to more severe cognitive
defects and, ﬁnally, to generalized dementia (Boxer and Miller,
2005). In familial FTD cases, the mutated locus has been identi-
ﬁed in the genes encoding tau (Hong et al., 1998; Hutton et al.,
1998), VCP (Watts et al., 2004), CHMP2B (Skibinski et al., 2005),
progranulin (Baker et al., 2006; Cruts et al., 2006), and C9ORF72
(DeJesus-Hernandez et al., 2011; Renton et al., 2011). Among
them, CHMP2B (Parkinson et al., 2006; Cox et al., 2010), VCP
(Johnson et al., 2010a), and C9ORF72 (DeJesus-Hernandez et al.,
2011; Renton et al., 2011; Stewart et al., 2012) have also been impli-
cated in ALS. Moreover, the RNA-binding proteins TDP-43 and
FUS have been strongly implicated in both FTD and ALS (Arai
et al., 2006; Neumann et al., 2006, 2009; Sreedharan et al., 2008;
Vance et al., 2009).
As described above, Dicer deletion in spinal motor neurons
mimics most of the clinical (e.g., progressive paralysis) and patho-
logical (e.g., astrocytosis and signs of axonopathy) features of ALS
(Haramati et al., 2010). Whether the miRNA pathway is involved
in the molecular pathogenesis of FTD/ALS caused by C9ORF72
repeat expansion is unknown. However, a potential involvement
for the miRNA pathway in other forms of FTD or ALS comes
from limited studies on TDP-43. TDP-43 is mutated in a subset of
ALS patients (Sreedharan et al., 2008), and the expression levels of
some miRNAs are affected in TDP-43 mutant ﬂies (Buratti et al.,
2010). Biochemical interactions between TDP-43 and Drosha,
a key miRNA processing enzyme (Han et al., 2004), have been
observed (Gregory et al., 2004; Ling et al., 2010). These ﬁndings
raise the possibility that TDP-43 may play a role in miRNA pro-
cessing; however, the mechanism remains to be elucidated and
whether endogenousDrosha andTDP-43 physically interact needs
to be demonstrated.
Some miRNAs are emerging as important contributors to ALS
pathogenesis. The muscle-speciﬁc miR-206 is upregulated upon
nerve injury and is required for regeneration of neuromuscu-
lar synapses. Moreover, miR-206 deﬁciency accelerates disease
progression in a mouse model of ALS (Williams et al., 2009). miR-
9/9∗, an evolutionarily conserved and multifunctional miRNA
(Yuva-Aydemir et al., 2011), is also potentially involved in ALS.
Proﬁling of miRNA expression in motor neurons harboring an
SMN1mut allele found in pediatric spinal motor atrophy revealed
decreases of more than 90% in miR-9 and miR-9∗ levels (Hara-
mati et al., 2010). More importantly, changes in the expression
levels of the neuroﬁlament subunits likely contribute to the dis-
ease, and miR-9 is an upstream regulator of the neuroﬁlament
mRNAs.
Several other miRNAs might be linked to FTD–ALS through
different mechanisms. For example, miR-29b and miR-107 reg-
ulate progranulin levels (Jiao et al., 2010; Wang et al., 2010b).
Since progranulin haploinsufﬁciency can cause FTD114,115, exces-
sive levels of those miRNAs might decrease progranulin levels and
be a risk factor for the disease. Consistent with these observa-
tions, a genetic polymorphism in the 3′UTR of the progranulin
gene is associated with a higher risk of FTD–ALS, and multiple
miRNAs are misregulated in FTD with TDP-43 pathology (Rade-
makers et al., 2008; Kocerha et al., 2011). This genetic variant
(rs5848) affects the miR-659 binding site, resulting in more efﬁ-
cient binding and, consequently, decreased progranulin levels. It is
not known whether translational regulation by miRNAs is a com-
mon mechanism in FTD caused by progranulin deﬁciency or in
other neurodegenerative diseases (Rollinson et al., 2011).
SUMMARY
Although much progress has been made in our understand-
ing of how miRNAs control gene expression at the post-
transcriptional level during development, their contributions
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FIGURE 2 | Potential mechanisms of neurodegeneration induced by
altered miRNA networks. Schematic representation of cellular pathways
that could be affected downstream of miRNAs. (1) Defects in miRNAs
could increase the levels of aggregation-prone proteins either directly (i.e.,
miR-106a and APP in AD) or indirectly (i.e., miR-107 acting through BACE1
or miR-137 acting through serine palmitoyltransferase in AD). (2) miRNAs
could control the expression of proteins involved in proper folding or quality
control, increasing the risk of protein aggregation. (3) miRNAs could impair
the removal of aggregated proteins and therefore increase their levels and
toxicity. (4) Finally, altered miRNAs might result in neuronal cell death due
to increased levels of certain transcription factors (i.e., miR-124 controls
neuronal survival by limiting the expression of Lhx2) or the imbalance
between pro-survival and pro-apoptotic signals (i.e., in FTD, polymorphism
rs5848 results in more efﬁcient binding of miR-659 and decreased levels of
the pro-survival factor progranulin).
to neurodegenerative disease remain poorly understood. Many
fundamental questions need to be addressed. Is miRNA pathway
disruption a downstream consequence or a cause of neurodegen-
eration (Figure 2 vs. Figure 3)? Are miRNAs essential for the
proper regulationof aggregation-proneproteins or do they control
additional pathogenic pathways? Are individual miRNAs espe-
cially important in particular neurodegenerative diseases? Which
miRNA target or targets are relevant for the disease? To address
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Loss of silencing activity
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FIGURE 3 | Potential mechanisms of miRNA deregulation downstream
of protein aggregation/dysfunction.Two basic mechanisms could affect
miRNA regulatory networks: (1) alteration of miRNA levels through
deregulation of transcription (i.e., miR-9 downstream of HTT and REST) or
processing (i.e., TDP-43 altering Drosha function) and (2) interference with
RISC activity (i.e., ataxin-2 seems to be required for optimal miRNA
silencing).
models, such as conditional knockouts in which developmental
defects can be circumvented, allowing assessment of the functions
of speciﬁc miRNAs in the adult brain. We expect many exciting
ﬁndings will be made in years to come.
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